Compare Wockhardt with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT vs GLENMARK PHARMA - Comparison Results

WOCKHARDT     Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT GLENMARK PHARMA WOCKHARDT/
GLENMARK PHARMA
 
P/E (TTM) x -54.4 16.9 - View Chart
P/BV x 1.2 2.3 51.6% View Chart
Dividend Yield % 0.0 0.4 0.7%  

Financials

 WOCKHARDT   GLENMARK PHARMA
EQUITY SHARE DATA
    WOCKHARDT
Mar-18
GLENMARK PHARMA
Mar-19
WOCKHARDT/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,012712 142.2%   
Low Rs532484 109.9%   
Sales per share (Unadj.) Rs355.9349.6 101.8%  
Earnings per share (Unadj.) Rs-60.332.8 -183.9%  
Cash flow per share (Unadj.) Rs-46.844.3 -105.5%  
Dividends per share (Unadj.) Rs0.012.00 0.5%  
Dividend yield (eoy) %00.3 0.4%  
Book value per share (Unadj.) Rs257.8198.6 129.8%  
Shares outstanding (eoy) m110.63282.17 39.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.21.7 126.9%   
Avg P/E ratio x-12.818.2 -70.2%  
P/CF ratio (eoy) x-16.513.5 -122.4%  
Price / Book Value ratio x3.03.0 99.5%  
Dividend payout %06.1 -0.3%   
Avg Mkt Cap Rs m85,379168,625 50.6%   
No. of employees `0006.312.0 52.0%   
Total wages/salary Rs m9,37120,561 45.6%   
Avg. sales/employee Rs Th6,295.08,196.0 76.8%   
Avg. wages/employee Rs Th1,498.31,708.1 87.7%   
Avg. net profit/employee Rs Th-1,066.3768.5 -138.8%   
INCOME DATA
Net Sales Rs m39,36998,655 39.9%  
Other income Rs m1,2022,081 57.8%   
Total revenues Rs m40,571100,736 40.3%   
Gross profit Rs m1815,858 0.1%  
Depreciation Rs m1,4953,259 45.9%   
Interest Rs m2,5553,346 76.4%   
Profit before tax Rs m-2,83011,335 -25.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,5821,672 -214.3%   
Tax Rs m2573,756 6.8%   
Profit after tax Rs m-6,6699,250 -72.1%  
Gross profit margin %016.1 0.3%  
Effective tax rate %-9.133.1 -27.4%   
Net profit margin %-16.99.4 -180.7%  
BALANCE SHEET DATA
Current assets Rs m33,79666,968 50.5%   
Current liabilities Rs m26,91740,211 66.9%   
Net working cap to sales %17.527.1 64.4%  
Current ratio x1.31.7 75.4%  
Inventory Days Days7983 95.2%  
Debtors Days Days8981 109.9%  
Net fixed assets Rs m39,66433,322 119.0%   
Share capital Rs m553282 196.0%   
"Free" reserves Rs m27,96855,770 50.1%   
Net worth Rs m28,52256,052 50.9%   
Long term debt Rs m21,73135,738 60.8%   
Total assets Rs m81,620132,888 61.4%  
Interest coverage x-0.14.4 -2.5%   
Debt to equity ratio x0.80.6 119.5%  
Sales to assets ratio x0.50.7 65.0%   
Return on assets %-5.09.5 -53.2%  
Return on equity %-23.416.5 -141.7%  
Return on capital %-7.717.8 -43.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m9,80762,998 15.6%   
Fx outflow Rs m1,78922,859 7.8%   
Net fx Rs m8,01940,140 20.0%   
CASH FLOW
From Operations Rs m68413,242 5.2%  
From Investments Rs m6,302-6,990 -90.2%  
From Financial Activity Rs m-7,695-7,387 104.2%  
Net Cashflow Rs m-664-2,971 22.4%  

Share Holding

Indian Promoters % 74.5 48.3 154.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.3 6.9 33.3%  
FIIs % 7.7 34.4 22.4%  
ADR/GDR % 0.1 0.0 -  
Free float % 15.4 10.5 146.7%  
Shareholders   67,757 56,727 119.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT With:   SANOFI INDIA  ABBOTT INDIA  PANACEA BIOTECH  WYETH LTD  GSK PHARMA  

Compare WOCKHARDT With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Flat; Telecom and Healthcare Stocks Witness Selling(Closing)

Indian share markets erased the opening gains and ended marginally lower for the second consecutive day today.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

WOCKHARDT Announces Quarterly Results (3QFY20); Net Profit Up 125.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, WOCKHARDT has posted a net profit of Rs 192 m (up 125.0% YoY). Sales on the other hand came in at Rs 9 bn (down 16.9% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

WOCKHARDT Announces Quarterly Results (1QFY20); Net Profit Up 57.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, WOCKHARDT has posted a net profit of Rs 369 m (up 57.2% YoY). Sales on the other hand came in at Rs 9 bn (down 14.3% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

More Views on News

Most Popular

Large Opportunities Are Coming Our Way

Aug 5, 2020

Kenneth Andrade tells us why stocks will bounce back strongly and what he's bullish on.

Is It Time to Book Profits in Gold and Silver?(Fast Profits Daily)

Aug 10, 2020

Gold and silver have delivered phenomenal returns this year. Is it time to take some money of the table?

Forget the Nifty and Sensex for the Next 1 or 2 Years and Focus on These Stocks(Profit Hunter)

Aug 6, 2020

Stocks from the essential small cap space are likely to be outperformers over the next 1 or 2 years.

This 20 Year Cycle Suggests Gold is Set for an August Rally(Profit Hunter)

Jul 31, 2020

The real reason why gold prices will go up more.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT SHARE PRICE


Aug 13, 2020 (Close)

TRACK WOCKHARDT

  • Track your investment in WOCKHARDT with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

WOCKHARDT 8-QTR ANALYSIS

COMPARE WOCKHARDT WITH

MARKET STATS